Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Neuropathol Exp Neurol ; 72(11): 1043-51, 2013 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-24128680

RESUMEN

Natalizumab, a monoclonal antibody directed against α4 integrins, has, to date, been associated with 399 cases of progressive multifocal leukoencephalopathy (PML) worldwide in patients receiving treatment for multiple sclerosis (MS). Because of the limited number of histologic studies, the possible interplay between MS and PML lesions has not been investigated. We report the clinical, radiologic, and histologic findings of an MS patient who developed PML after 32 months of natalizumab monotherapy. After withdrawal of natalizumab, she received plasma exchange, mefloquine, and mirtazapine but died soon thereafter. Postmortem examination was restricted to examination of the brain and spinal cord. Extensive PML lesions, characterized by the presence of JC virus DNA were found in the cerebral white matter and neocortex. Sharply demarcated areas of active PML lesions contained prominent inflammatory infiltrates composed of approximately equal numbers of CD4-positive and CD8-positive T cells, consistent with an immune reconstitution inflammatory syndrome. Conversely, all MS lesions identified were hypocellular, long-standing inactive plaques characterized by myelin loss, relative axonal preservation, and gliosis and, importantly, were devoid of JC virus DNA and active inflammation. Chronic inactive MS lesions were separate and distinct from nearby PML lesions. This case demonstrates the coexistence and apparent lack of interplay between chronic inactive MS and PML lesions, and that immune reconstitution inflammatory syndrome seems to affect the shape and appearance of PML but not MS lesions.


Asunto(s)
Anticuerpos Monoclonales Humanizados/efectos adversos , Encéfalo/patología , Leucoencefalopatía Multifocal Progresiva/inducido químicamente , Esclerosis Múltiple/tratamiento farmacológico , Médula Espinal/patología , Anticuerpos Monoclonales Humanizados/uso terapéutico , Autopsia , Femenino , Humanos , Leucoencefalopatía Multifocal Progresiva/patología , Persona de Mediana Edad , Esclerosis Múltiple/patología , Natalizumab
2.
Handb Clin Neurol ; 100: 271-6, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21496586

RESUMEN

Polycythemia vera is a sporadic myeloproliferative disorder of increased red blood cell mass affecting multiple organ systems. Associated thrombosis, hemorrhaging, and hyperviscosity commonly result in neurological manifestations, sometimes in the form of chorea and ballism. Resultant choreiform movements have been mainly described as generalized with orofaciolingual and appendicular muscle involvement, hypotonia, and hyporeflexia. Chorea has also been uncommonly reported as arising from secondary causes of polycythemia; however, the underlying pathophysiology has not been clearly elucidated. Proposed mechanisms for basal ganglia dysfunction include hypoperfusion due to venous stasis, receptor hypersensitivity in a setting of reduced catecholamine levels, and altered platelet dopamine metabolism. Magnetic resonance imaging and single-photon emission computed tomography perfusion studies have failed to reveal an anatomical or physiological basis for polycythemia vera-associated chorea, yet rare pathological examinations of deceased patients have shown signs of cerebral venous thrombosis and perivenous demyelination. Administration of neuroleptics may suppress abnormal choreiform movement; however, effective management of polycythemia vera requires serial venesections in conjunction with chemotherapy. Appropriate treatment may prolong survival to more than 10 years, although chorea may spontaneously remit, re-emerge with resurgence of disease, or continue indefinitely despite maintenance therapy.


Asunto(s)
Corea/complicaciones , Policitemia/complicaciones , Corea/diagnóstico , Corea/epidemiología , Corea/etiología , Humanos , Policitemia/diagnóstico , Policitemia/epidemiología , Policitemia/etiología , Factores de Riesgo
3.
J Nucl Med ; 48(5): 776-82, 2007 May.
Artículo en Inglés | MEDLINE | ID: mdl-17475967

RESUMEN

UNLABELLED: Conventional visual analysis of brain (18)F-FDG PET scans is useful for predicting postsurgical improvement for temporal lobe epilepsy (TLE) patients, but prognostic value for identifying patients who will achieve seizure-free status is considerably lower. We aimed to develop an approach with which to quantitatively assess prognostically pertinent aspects of metabolic asymmetry in presurgical PET scans for forecasting postsurgical seizure-free clinical outcomes. METHODS: Presurgical brain PET scans of 75 TLE patients were examined using a display/analysis tool that quantified maximal metabolic asymmetry in a specified proportion (x%) of the temporal lobe pixels in the most asymmetric plane, generating a temporal lobe asymmetry index (T-AI(x)). Results of this analysis were compared with patients' actual postsurgical outcomes after an average of approximately 4 y of clinical follow-up. The investigation was divided into 2 main steps: The PET scans examined in the first step, selected by chronological order of scan acquisition dates, comprised just less than two thirds of the patient group studied (n=47) and were used to look for parameters predicting seizure-free postsurgical outcome; in the second step, the predictive value of the parameters suggested by the analysis in the first step was independently examined using the set of remaining PET scans (n=28) to check for wider applicability of the approach. RESULTS: Of the 75 patients studied, 42 became seizure free after surgery, whereas 33 continued to seize beyond the immediate postoperative period, during a mean 3.8-y follow-up interval. The specified proportion of temporal pixels with which to assess maximal asymmetry that provided the highest prognostic value with respect to achieving seizure-free status was 20%. Across the study population, those patients with scans having lower T-AI(20) values (corresponding to <40% difference in pixel intensities between left and right temporal lobes, among the 20% most asymmetric left-right pixel pairs measured in the most asymmetric plane) were only half as likely to continue to have seizures postsurgically as those with scans having higher T-AI(20) values (positive likelihood ratio for achieving seizure-free outcome, 1.98; 95% confidence interval, 1.07-3.67). Overall, those patients with greater maximal asymmetry, as indexed by higher T-AI(20) values, had a significantly decreased chance of achieving seizure-free status after surgery than those with lower degrees of asymmetry (P=0.017), and this same tendency was observed for both the first and second series of PET scans examined. CONCLUSION: A quantifying approach to assessing maximal temporal asymmetry over a specified proportion of the temporal lobe may help to predict whether patients will likely be free of seizures during the years after neurosurgical resection of epileptogenic tissue.


Asunto(s)
Epilepsia del Lóbulo Temporal/diagnóstico por imagen , Epilepsia del Lóbulo Temporal/metabolismo , Epilepsia del Lóbulo Temporal/cirugía , Fluorodesoxiglucosa F18/farmacocinética , Interpretación de Imagen Asistida por Computador/métodos , Tomografía de Emisión de Positrones/métodos , Adulto , Algoritmos , Encéfalo/diagnóstico por imagen , Encéfalo/metabolismo , Femenino , Humanos , Aumento de la Imagen/métodos , Masculino , Pronóstico , Radiofármacos/farmacocinética , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA